The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC).
G. Scambia
No relevant relationships to disclose
D. Lorusso
No relevant relationships to disclose
G. Amadio
No relevant relationships to disclose
N. Trivellizzi
No relevant relationships to disclose
A. Pietragalla
No relevant relationships to disclose
R. De Vincenzo
No relevant relationships to disclose
V. Salutari
No relevant relationships to disclose
M. Di Stefano
No relevant relationships to disclose
G. Mangili
No relevant relationships to disclose
S. Montoli
No relevant relationships to disclose
G. Citterio
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.